Double trouble: psoriasis and cardiometabolic disorders.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
diabetes mellitus 2 endocrinologydiseases
metabolic syndrome 2 endocrinologydiseases
obesity 11 endocrinologydiseases
pioglitazone 1 endocrinologydiseasesdrugs
type 2 diabetes mellitus 1 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
pioglitazone 20971 clinical trials are available to date.Impact of therapies for co-morbiditiesThe anti-diabetic drugs pioglitazone [81] and glucagon-like peptide 1 (GLP 1) agonists[82] have been shown to improve PsO. Pioglitazone is
Select Disease Character Offset Disease Term Instance
diabetes mellitus 5784 cardiovascular death, by as much as 50%.[32] The traditional Framingham risk factors such as type 2 diabetes mellitus (T2DM), hypertension and smoking have been shown to only partly account for the increased cardiometabolic
diabetes mellitus 8658 with severe PsO were at increased risk for death from CVD–1.57 (1.26–1.96)HT, hypertension; DM, diabetes mellitus ; BMI, body mass index; MI, myocardial infarction.Table 3Longitudinal studies arising from the Danish
metabolic syndrome 3411 in combination with the terms ‘cardiovascular disease’, ‘co-morbidities’, ‘diabetes’, ‘ metabolic syndrome ’, ‘obesity’, ‘hypertension’, ‘dyslipidaemia’, ‘non-alcoholic fatty liver disease’
metabolic syndrome 5134 spectrum of cardiometabolic co-morbidities observed in subjects with PsO. These include obesity,[15] the metabolic syndrome (MetS) and its components,[13],[16] non-alcoholic fatty liver disease (NAFLD)[22] and CVD[10],[19],[20],[26]-[28]
obesity 1144 cardiovascular morbidity and mortality. Factors linking PsO and CMD include: chronic inflammation, obesity , classic cardiovascular risk factors, and the effects of systemic therapy used to treat PsO. Chronic
obesity 1306 of systemic therapy used to treat PsO. Chronic inflammation is associated with PsO itself, and with obesity . Adipose tissue is responsible for the secretion of various adipokines, which together with pro-inflammatory
obesity 3437 terms ‘cardiovascular disease’, ‘co-morbidities’, ‘diabetes’, ‘metabolic syndrome’, ‘ obesity ’, ‘hypertension’, ‘dyslipidaemia’, ‘non-alcoholic fatty liver disease’ and ‘inflammation’.
obesity 5117 on the wide spectrum of cardiometabolic co-morbidities observed in subjects with PsO. These include obesity ,[15] the metabolic syndrome (MetS) and its components,[13],[16] non-alcoholic fatty liver disease (NAFLD)[22]
obesity 11853 1.62–2.43).[13] Furthermore, systematic reviews suggest that individual components of the MetS (dysglycaemia, obesity and hypertension) occur more frequently in PsO patients[15],[42],[43] (Table 4).Table 4Systematic reviews
obesity 12024 patients[15],[42],[43] (Table 4).Table 4Systematic reviews showing association of type 2 diabetes, hypertension and obesity with psoriasisOdds ratioRisk factorNo of StudiesOverallMild PsOSevere PsOType 2 diabetes[22]271.59 (1.38–1.83)1.53
obesity 12698 moderate to severe cutaneous PsO.[44] Studies have also shown that PsO is associated with abdominal obesity , which is a proxy measure of visceral adipose tissue, and is a well-recognised risk factor for T2DM,
obesity 16267 sensitivity.[60]Possible genetic linksEpidemiological studies suggest a common genetic link between PsO, T2DM and obesity . In a 2016 cross-sectional, populationbased twin study in 33 588 Danish subjects, a significant association
obesity 16405 populationbased twin study in 33 588 Danish subjects, a significant association between PsO, T2DM and obesity was observed.[61] Analysing data from twins discordant for PsO and including both monozygotic and dizygotic
obesity 16595 monozygotic and dizygotic twin pairs, the study observed evidence for a shared genetic aetiology of obesity and PsO.Moreover, there is evidence indicating that the strongest predictor of major adverse cardiovascular
obesity 17534 and as discussed previously, there are higher prevalences of T2DM, dyslipidaemia, hypertension and obesity in subjects with PsO. Furthermore, it is known that patients with PsO have a higher prevalence of smoking
type 2 diabetes mellitus 5777 premature cardiovascular death, by as much as 50%.[32] The traditional Framingham risk factors such as type 2 diabetes mellitus (T2DM), hypertension and smoking have been shown to only partly account for the increased cardiometabolic

You must be authorized to submit a review.